Simplified Summary
PT-141 (bremelanotide) is a synthetic cyclic peptide that functions as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. It was derived from Melanotan-II through structural modification and has been studied in preclinical settings for its central nervous system melanocortin receptor engagement, particularly at MC3R and MC4R subtypes expressed in hypothalamic and limbic brain regions associated with sexual behaviour regulation.
In preclinical behavioural neuroscience research, PT-141 has been studied in animal models examining melanocortin-regulated aspects of sexual behaviour. Rodent model studies have used standardised sexual behaviour paradigms to characterise how central melanocortin receptor agonism by PT-141 influences behavioural endpoints in laboratory settings.
Key Findings Reported in Preclinical Models
- Central nervous system melanocortin receptor engagement characterised in preclinical pharmacokinetic and receptor distribution studies.
- Sexual behaviour outcomes in preclinical rodent model paradigms under PT-141 administration, with dose-response characterisation.
- MC3R and MC4R receptor selectivity profiling in cell-based binding and functional assays.
- Hypothalamic and limbic system activity changes in animal model neuroimaging and neurochemical studies following PT-141 administration.
Introduction
The central melanocortin system, particularly MC3R and MC4R expressed in the hypothalamus, has been implicated in the regulation of sexual motivation and behaviour through preclinical genetic and pharmacological studies. PT-141 was developed as a research tool for studying central melanocortin receptor biology in the context of sexual behaviour neuroscience, and has been characterised in preclinical animal model systems for its receptor engagement profile and CNS distribution.
Research Applications
- Central melanocortin receptor biology research using PT-141 to characterise MC3R and MC4R pharmacology and downstream signalling in CNS model systems.
- Behavioural neuroscience research in preclinical animal models examining melanocortin-regulated aspects of motivation and behaviour.
- Comparative melanocortin agonist pharmacology research contrasting PT-141's receptor engagement profile with other melanocortin compounds.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.